SCHEMBL1729317

SCHEMBL1729317

CCCC[C@H](N)c1ccccc1OC(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNK3 O14649 1/20 0.35
KCNK9 Q9NPC2 1/20 0.35
SLC7A5 Q01650 3/20 0.34
IKBKB O14920 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
CETP P11597 1/20 0.33
CYP2D6 P10635 1/20 0.33
KCNH2 Q12809 1/20 0.33
HSD11B1 P28845 1/20 0.33
SLC2A1 P11166 1/20 0.33
F2R P25116 1/20 0.33
EGFR P00533 2/20 0.32
DHFR P00374 1/20 0.32
PPARG P37231 2/20 0.32
PDE2A O00408 2/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1727984 1.00 CYP1A2 (0.36) CYP1A2CYP2C9CYP2C19KCNK3KCNK9
SCHEMBL16442486 0.86 KCNK3 (0.39) CYP1A2CYP2C9CYP2C19KCNK3KCNK9
SCHEMBL21264288 0.86 KCNK3 (0.39) CYP1A2CYP2C9CYP2C19KCNK3KCNK9
SCHEMBL1727979 0.84 ALDH1A1 (0.39) KCNK3KCNK9SLC6A2SLC6A4CYP2D6
SCHEMBL1727859 0.84 ALDH1A1 (0.39) KCNK3KCNK9SLC6A2SLC6A4CYP2D6
SCHEMBL12261514 0.84 ALDH1A1 (0.39) KCNK3KCNK9SLC6A2SLC6A4CYP2D6
Hydrochloric Acid SCHEMBL16563567 0.83 ALDH1A1 (0.38) KCNK3KCNK9SLC6A2SLC6A4CYP2D6
SCHEMBL27568621 0.82 TSHR (0.43) CYP1A2CYP2C9CYP2C19EGFRDHFR
SCHEMBL22639546 0.82 KCNK3 (0.38) KCNK3KCNK9SLC7A5SLC6A2SLC6A4
SCHEMBL19505951 0.82 DHFR (0.37) CYP1A2CYP2C9CYP2C19KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1530562-B1 OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME CENTRAL GLASS CO LTD (JP) 2011-11-30 EP disclosed
US-7368609-B2 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2008-05-06 US disclosed
US-20070142670-A1 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same CENTRAL GLASS CO., LTD. (JP) 2007-06-21 US disclosed
US-7186865-B2 Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture CENTRAL GLASS COMPANY, LIMITED (JP) 2007-03-06 US disclosed
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same NAT1, PNMT, AFF1 CYP1A2 129/4885CYP2C9 546/4885CYP2C19 609/4885
US-20070142670-A1 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same NAT1, AFF1, PNMT CYP1A2 99/4885CYP2C9 438/4885CYP2C19 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.